Villejuif

• A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Pos … Ended
  2023-506038-65-00 4 2024-04-15 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CA
• A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid Tumors Ended
  2022-500823-61-00 7 2024-04-08 Advanced Solid Tumours
• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of vepdegestrant (ARV-471) in Combination With Other Medicines … Ended
  2023-507125-41-00 9 2024-03-25 Advanced or Metastatic Breast Cancer
• FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC Ended
  2023-505145-93-00 7 2024-03-21 Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma
• A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 … Ended
  2023-506354-20-00 1 2024-02-20 Small Cell Lung Cancer and Neuroendocrine Carcinoma
• A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or M … Ended
  2023-507321-42-00 1 2024-02-15 Myelodysplastic syndrome (MDS)
• (VELA) Study of BLU-222 in Advanced Solid Tumors Ended
  2022-502528-29-00 7 2024-01-09 HR+ Breast Cancer CCNE1 Amplification HER2-negative Breast Cancer Adva
• A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, an … Ended
  2023-505576-29-00 7 2024-01-03 Advanced solid tumors
• A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma. Ended
  2023-503739-16-00 1 2023-12-20 Relapsed or refractory solid tumors or non-Hodgkin lymphoma
• A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors Ended
  2022-502348-11-00 1 2023-12-15 Pancreatic Neoplasms
• Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien … Ended
  2022-502584-38-00 5 2023-12-12 Locally advanced squamous cell carcinoma of the head and neck
• Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors Ended
  2024-518411-19-00 9 2023-12-04 Advanced HER2-Expressing Solid Tumors.
• Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic C … Ended
  2023-503270-20-00 3 2023-11-29 recurrent or metastatic Adenoid Cystic Carcinoma of the Head and Neck
• A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular C … Ended
  2022-502840-11-00 9 2023-11-28 Hepatocellular Carcinoma (Morpheus-Neo HCC)
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma Ended
  2023-503418-63-00 4 2023-11-23 Head and Neck Squamous Cell Carcinoma
• AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEW … Ended
  2023-504545-31-00 1 2023-11-23 colorectal cancer
• A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended
  2022-502476-23-00 4 2023-10-25 Treatment of immunotherapy-naive patients with previously untreated or
• Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me … Ended
  2022-502372-22-01 4 2023-10-19 Metastatic Breast Cancer HR+, HER2-
• A Study of NB003 in Patients With Advanced Malignancies Ended
  2022-502401-15-00 7 2023-10-19 Gastrointestinal stromal tumor
• A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patient … Ended
  2024-511007-41-00 9 2023-10-03 Untreated advanced or metastatic non-squamous non-small cell lung canc
• Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors Ended
  2022-502867-39-00 1 2023-09-29 Advanced solid tumors including non-small cell lung cancer (NSCLC), me
• Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors Ended
  2022-502787-20-00 4 2023-09-28 Melanoma and squamous cell carcinoma of the head and neck
• A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2022-502850-14-00 1 2023-09-25 gastroesophageal junction
• A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors Ended
  2022-500930-27-00 3 2023-09-15 Solid Tumor

Showing 793–816 of 961 trials